Ono Pharma Submits Application For Manufacturing And Marketing Approval Of Ripretinib

Ono Pharmaceutical submitted an application for manufacturing and marketing approval of ripretinib (DCC-2618) for gastrointestinal stromal tumor after progression on prior therapy. The drug was developed by Deciphera, and the submission is a positive regulatory milestone that enables potential commercialization pending review. Approval is not guaranteed, so near-term market impact should be limited while regulators evaluate the application.

Analysis

Ono Pharmaceutical submitted an application for manufacturing and marketing approval of ripretinib (DCC-2618) for gastrointestinal stromal tumor after progression on prior therapy. The drug was developed by Deciphera, and the submission is a positive regulatory milestone that enables potential commercialization pending review. Approval is not guaranteed, so near-term market impact should be limited while regulators evaluate the application.